Le Travenues Technology Limited (NSE:IXIGO)

Theseus Pharmaceuticals Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Cash & Equivalents	-	2,790	645.72	731.25	407.17	201.05
Short-Term Investments	-	894.39	5.62	-	638.2	104.34
Trading Asset Securities	-	-	522.47	453.88	-	-
Cash & Short-Term Investments	3,684	3,684	1,174	1,185	1,045	305.39
Cash Growth	178.82%	213.85%	-0.95%	13.37%	242.31%	-4.38%
Accounts Receivable	-	366.85	283.13	121.16	86.19	263.31
Other Receivables	-	-	143.75	102.96	103.65	9.17
Receivables	-	368.11	427.28	249.79	189.84	272.48
Prepaid Expenses	-	-	43.03	61.89	139.83	17.04
Restricted Cash	-	-	12.5	27.54	-	-
Other Current Assets	-	1,575	1,038	968.26	954.09	109.6
Total Current Assets	-	5,627	2,695	2,493	2,329	704.51
Property, Plant & Equipment	-	89.95	45.44	117.19	41.27	37.38
Long-Term Investments	-	349.39	517.21	71.31	57.6	3.44
Goodwill	-	2,596	2,483	2,585	2,541	816.97
Other Intangible Assets	-	178.69	181.61	295.18	303.8	141.75
Long-Term Accounts Receivable	-	-	13.05	7.45	-	-
Long-Term Deferred Tax Assets	-	86.86	259.28	158.92	5.01	51.19
Other Long-Term Assets	-	127.21	126.81	131.83	106.53	95.47
Total Assets	-	9,055	6,321	5,859	5,385	1,851
Accounts Payable	-	1,035	568.79	360.85	445.36	195.18
Accrued Expenses	-	80.33	316.38	402.03	218.3	95.81
Short-Term Debt	-	323.69	400.76	5.35	27.31	50.97
Current Portion of Leases	-	40.56	35.17	31.64	12.49	8.71
Current Unearned Revenue	-	217.54	115.2	91.48	52.14	40.07
Other Current Liabilities	-	876.02	344.82	671.49	607.57	651.96
Total Current Liabilities	-	2,573	1,781	1,563	1,363	1,043
Long-Term Debt	-	-	-	-	-	98.44
Long-Term Leases	-	37.57	24.52	63.3	30.9	43.38
Long-Term Deferred Tax Liabilities	-	11.76	-	25.2	28.84	37.33
Other Long-Term Liabilities	-	-	-	295.58	507.2	310.93
Total Liabilities	-	2,694	1,861	1,988	1,958	1,551
Common Stock	-	390.11	372.97	371.2	369.75	0.43
Additional Paid-In Capital	-	-	5,749	6,108	6,058	370.6
Retained Earnings	-	-	-2,062	-3,064	-3,215	-2,574
Comprehensive Income & Other	-	5,946	399.62	322.48	213.77	177
Total Common Equity	6,336	6,336	4,460	3,738	3,427	-2,026
Minority Interest	-	25.1	-	133.55	-	-
Shareholders' Equity	6,361	6,361	4,460	3,871	3,427	299.38
Total Liabilities & Equity	-	9,055	6,321	5,859	5,385	1,851
Total Debt	401.82	401.82	460.45	100.29	70.7	201.5
Net Cash (Debt)	3,282	3,282	713.36	1,085	974.67	103.89
Net Cash Growth	281.27%	360.10%	-34.24%	11.30%	838.18%	-
Net Cash Per Share	8.42	8.45	1.87	2.84	2.64	0.35
Filing Date Shares Outstanding	389.49	388.77	372.97	371.2	369.75	172.51
Total Common Shares Outstanding	389.49	388.77	372.97	371.2	369.75	172.51
Working Capital	-	3,054	913.76	929.77	965.96	-338.19
Book Value Per Share	16.30	16.30	11.96	10.07	9.27	-11.75
Tangible Book Value	3,562	3,562	1,795	857.7	581.69	-2,985
Tangible Book Value Per Share	9.16	9.16	4.81	2.31	1.57	-17.30
Machinery	-	-	45.45	38.26	29.71	10.1
Construction In Progress	-	-	-	28.89	-	-

Updated Jan 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.